What question did this study set out to answer?

To compare the efficacy and safety of NAB-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as induction chemotherapy for LA-NPC.

December 8, 2025Therapeutic Advances in Medical OncologyOpen Access

NAB-paclitaxel and cisplatin versus gemcitabine and cisplatin as induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis

View Full Paper

Ask AI

Bookmark

Authors

YLYou‐Ping Liu

Discussion

Member takes

Implication

Retrospective analysis shows comparable progression-free survival with NAB-paclitaxel and gemcitabine in advanced nasopharyngeal cancer, suggesting balanced efficacy and safety profiles.

Key Points

To compare the efficacy and safety of NAB-paclitaxel plus cisplatin versus gemcitabine plus cisplatin as induction chemotherapy for LA-NPC.
Retrospective analysis of LA-NPC patients treated at Sun Yat-sen University Cancer Center.
Propensity score matching was used to balance baseline characteristics between treatment groups.
Patients received either NAB-TP or GP followed by concurrent chemoradiotherapy.
908 patients with LA-NPC were enrolled, with 197 in the NAB-TP group.
No significant differences were found in overall survival and progression-free survival before and after matching.
The NAB-TP group showed significantly lower incidences of anemia and thrombocytopenia compared to the GP group.

Cite This Study

You‐Ping Liu (2025) studied this question.

synapsesocial.com/papers/693624ad4fa91c937236c752 https://doi.org/10.1177/17588359251400977

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis shows comparable progression-free survival with NAB-paclitaxel and gemcitabine in advanced nasopharyngeal cancer, suggesting balanced efficacy and safety profiles.

NAB-paclitaxel and cisplatin versus gemcitabine and cisplatin as induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

NAB-paclitaxel and cisplatin versus gemcitabine and cisplatin as induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider